Takahide Nejo

Oct 27, 2023 | biorxiv.org | Takahide Nejo |Lin Wang |Kevin Leung |Albert Wang

AbstractBackground: Despite advancements in cancer immunotherapy, solid tumors remain formidable challenges. In glioma, profound inter- and intra-tumoral heterogeneity hamper therapeutic development. Therefore, it is critical to consider alternative sources to expand the repertoire of targetable (neo-)antigens and improve therapeutic outcomes. Accumulating evidence suggests that tumor-specific alternative splicing (AS) could be an untapped reservoir of neoantigens.